用于不可治愈的复发性/转移性头颈部鳞状细胞癌（RM HNSCC）的程序性细胞死亡1抑制剂的新型联合用药：卡博替尼是领跑者吗？ - Suppr

Suppr

超能文献

Novel combinations with programmed cell death 1 inhibitor for incurable recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC): is cabozantinib a front runner?

作者信息

Bhateja Priyanka, Bonomi Marcelo, Verschraegen Claire

机构信息

Department of Medical Oncology, Ohio State University, James Cancer Center, Columbus, OH, USA.

出版信息

Transl Cancer Res. 2025 May 30;14(5):2548-2552. doi: 10.21037/tcr-2024-2569. Epub 2025 May 13.

DOI:10.21037/tcr-2024-2569

PMID:40530149

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12170040/

Abstract

摘要

相似文献

Novel combinations with programmed cell death 1 inhibitor for incurable recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC): is cabozantinib a front runner?用于不可治愈的复发性/转移性头颈部鳞状细胞癌（RM HNSCC）的程序性细胞死亡1抑制剂的新型联合用药：卡博替尼是领跑者吗？

Transl Cancer Res. 2025 May 30;14(5):2548-2552. doi: 10.21037/tcr-2024-2569. Epub 2025 May 13.

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.程序性细胞死亡受体 1（PD-1）抑制剂联合同期放化疗治疗复发性/转移性头颈部鳞状细胞癌患者的协同作用的初步分析。

Radiat Oncol. 2023 Jul 4;18(1):109. doi: 10.1186/s13014-023-02310-8.

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.头颈部鳞状细胞癌中的免疫检查点抑制剂：3期临床试验的系统评价

World J Clin Oncol. 2022 May 24;13(5):388-411. doi: 10.5306/wjco.v13.i5.388.

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗在含铂化疗期间或之后出现疾病进展的复发性或转移性头颈部鳞状细胞癌。

Oncologist. 2017 Jul;22(7):873-878. doi: 10.1634/theoncologist.2016-0496. Epub 2017 May 22.

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.新辅助和辅助帕博利珠单抗治疗局部晚期头颈癌

N Engl J Med. 2025 Jul 3;393(1):37-50. doi: 10.1056/NEJMoa2415434. Epub 2025 Jun 18.

Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial.雷莫芦单抗联合帕博利珠单抗治疗复发性或转移性头颈部鳞状细胞癌：一项单中心、1/2 期试验。

Lancet Oncol. 2024 Jul;25(7):888-900. doi: 10.1016/S1470-2045(24)00204-3. Epub 2024 Jun 5.

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.帕博利珠单抗联合或不联合化疗用于复发性或转移性头颈部鳞状细胞癌：III期随机KEYNOTE-048研究的5年随访结果

Eur J Cancer. 2025 May 15;221:115395. doi: 10.1016/j.ejca.2025.115395. Epub 2025 Apr 4.

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.卡博替尼与西妥昔单抗联合治疗复发性或转移性头颈部鳞状细胞癌的 1 期研究。

Oral Oncol. 2024 Jul;154:106861. doi: 10.1016/j.oraloncology.2024.106861. Epub 2024 May 24.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。

Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.LiGeR-HN关于培托西单抗+帕博利珠单抗和培托西单抗单药治疗复发性或转移性头颈部鳞状细胞癌的III期试验。

Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13.

本文引用的文献

A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).莫纳利珠单抗与度伐利尤单抗治疗复发/转移性头颈部鳞状细胞癌的II期研究：EORTC-HNCG-1559试验（UPSTREAM）I2队列的结果

ESMO Open. 2025 Apr 30;10(5):104554. doi: 10.1016/j.esmoop.2025.104554.

Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.帕博利珠单抗联合卡博替尼治疗复发性和/或转移性头颈部鳞状细胞癌：基于生物标志物分析的长期生存更新。

Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202.

Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.派姆单抗联合卡博替尼治疗复发性转移性头颈部鳞状细胞癌：一项 2 期临床试验。

Nat Med. 2023 Apr;29(4):880-887. doi: 10.1038/s41591-023-02275-x. Epub 2023 Apr 3.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.度伐利尤单抗联合或不联合曲美木单抗对比EXTREME方案作为复发性或转移性头颈部鳞状细胞癌一线治疗的疗效：KESTREL，一项随机、开放标签的III期研究。

Ann Oncol. 2023 Mar;34(3):262-274. doi: 10.1016/j.annonc.2022.12.008. Epub 2022 Dec 16.

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.纳武利尤单抗联合伊匹木单抗对比 EXTREME 方案作为复发/转移性头颈部鳞癌一线治疗：CheckMate 651 的最终结果。

J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6.

Immunotherapy for head and neck cancer: Present and future.头颈部癌症的免疫治疗：现状与未来。

Crit Rev Oncol Hematol. 2022 Jun;174:103679. doi: 10.1016/j.critrevonc.2022.103679. Epub 2022 Apr 6.

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.复发和/或转移性头颈部鳞状细胞癌中同步西妥昔单抗和纳武利尤单抗的多机构 II 期临床试验结果。

Clin Cancer Res. 2022 Jun 1;28(11):2329-2338. doi: 10.1158/1078-0432.CCR-21-3849.

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.卡博替尼的免疫原性细胞死亡及免疫调节作用

Front Oncol. 2021 Oct 20;11:755433. doi: 10.3389/fonc.2021.755433. eCollection 2021.

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.帕博利珠单抗联合西妥昔单抗治疗复发性或转移性头颈部鳞状细胞癌患者的开放标签、多臂、非随机、多中心、2 期临床试验。

Lancet Oncol. 2021 Jun;22(6):883-892. doi: 10.1016/S1470-2045(21)00136-4. Epub 2021 May 11.

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.双功能融合蛋白靶向 TGF-β和 PD-L1 的 Bintrafusp alfa 治疗头颈部鳞状细胞癌的 I 期队列研究结果。

J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000664.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验